Osimertinib 80 mg/40 mg
D5162C00048
Phase 2 small_molecule active
Quick answer
Osimertinib 80 mg/40 mg for Stage II-IIIB Non-small Cell Lung Carcinoma is a Phase 2 program (small_molecule) at AstraZeneca with 1 ClinicalTrials.gov record(s).
Program details
- Company
- AstraZeneca
- Indication
- Stage II-IIIB Non-small Cell Lung Carcinoma
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active